Do analysts rate MGX or BFRG?

Metagenomi presently has a consensus target price of $7.00, suggesting a potential upside of 464.52%. Given Metagenomi's stronger consensus rating and higher probable upside, equities analysts plainly believe Metagenomi is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is MGX or BFRG more profitable?

Bullfrog AI has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -51.23% -36.62% Bullfrog AI N/A -217.80% -174.57%

Do analysts rate SCYX or BFRG?

SCYNEXIS presently has a consensus target price of $24.00, indicating a potential upside of 462.06%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities analysts clearly believe SCYNEXIS is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is SCYX or BFRG more profitable?

Bullfrog AI has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets SCYNEXIS -41.79% -57.16% -39.48% Bullfrog AI N/A -217.80% -174.57%

Do analysts prefer BFRG or DWTX?

Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 769.57%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BFRG or DWTX more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -217.80% -174.57% Dogwood Therapeutics N/A -108.57% -30.28%

Do analysts prefer BFRG or HYPD?

Hyperion DeFi has a consensus target price of $6.95, suggesting a potential upside of 153.65%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Hyperion DeFi 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is BFRG or HYPD more profitable?

Hyperion DeFi's return on equity of -91.59% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -217.80% -174.57% Hyperion DeFi N/A -91.59% -73.08%

Which has higher valuation & earnings, ATHE or BFRG?

Bullfrog AI has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Bullfrog AI $116.67K 102.57 -$6.50M -$0.54 N/A

Is ATHE or BFRG more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Bullfrog AI N/A -217.80% -174.57%

Bullfrog AI (BFRG) Competitors

$0.65 +0.01 (+2.12%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$0.64 -0.01 (-1.61%)

As of 07/17/2026 07:45 PM Eastern

Compare

BFRG vs. MGX, SCYX, DWTX, HYPD, and ATHE

Should you buy Bullfrog AI stock or one of its competitors? MarketBeat compares Bullfrog AI with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bullfrog AI include Metagenomi (MGX), SCYNEXIS (SCYX), Dogwood Therapeutics (DWTX), Hyperion DeFi (HYPD), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry.

How does Bullfrog AI compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

1.0% of Bullfrog AI shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Metagenomi has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.8, suggesting that its stock price is 380% less volatile than the broader market.

In the previous week, Metagenomi had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 1 mentions for Metagenomi and 0 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.43 beat Metagenomi's score of 0.93 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Metagenomi	Positive
Bullfrog AI	Positive

Bullfrog AI has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Bullfrog AI	N/A	-217.80%	-174.57%

Metagenomi presently has a consensus target price of $7.00, suggesting a potential upside of 464.52%. Given Metagenomi's stronger consensus rating and higher probable upside, equities analysts plainly believe Metagenomi is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Bullfrog AI has lower revenue, but higher earnings than Metagenomi. Bullfrog AI is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.85	-$87.87M	-$2.30	N/A
Bullfrog AI	$116.67K	102.57	-$6.50M	-$0.54	N/A

Summary

Metagenomi beats Bullfrog AI on 10 of the 17 factors compared between the two stocks.

How does Bullfrog AI compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

SCYNEXIS has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.8, suggesting that its stock price is 380% less volatile than the broader market.

Bullfrog AI has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Bullfrog AI	N/A	-217.80%	-174.57%

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 14.7% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bullfrog AI has lower revenue, but higher earnings than SCYNEXIS. Bullfrog AI is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.06	-$8.61M	-$3.84	N/A
Bullfrog AI	$116.67K	102.57	-$6.50M	-$0.54	N/A

In the previous week, SCYNEXIS's average media sentiment score of 1.89 beat Bullfrog AI's score of 1.43 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Overall Sentiment
SCYNEXIS	Very Positive
Bullfrog AI	Positive

SCYNEXIS presently has a consensus target price of $24.00, indicating a potential upside of 462.06%. Given SCYNEXIS's stronger consensus rating and higher possible upside, equities analysts clearly believe SCYNEXIS is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

SCYNEXIS beats Bullfrog AI on 10 of the 15 factors compared between the two stocks.

How does Bullfrog AI compare to Dogwood Therapeutics?

Bullfrog AI (NASDAQ:BFRG) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 1 mentions for Dogwood Therapeutics and 0 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.43 beat Dogwood Therapeutics' score of 0.48 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Overall Sentiment
Bullfrog AI	Positive
Dogwood Therapeutics	Neutral

Bullfrog AI has a beta of -2.8, suggesting that its stock price is 380% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market.

Dogwood Therapeutics' return on equity of -108.57% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 769.57%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 14.7% of Bullfrog AI shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bullfrog AI has higher revenue and earnings than Dogwood Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116.67K	102.57	-$6.50M	-$0.54	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Summary

Dogwood Therapeutics beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.

How does Bullfrog AI compare to Hyperion DeFi?

Bullfrog AI (NASDAQ:BFRG) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Hyperion DeFi's return on equity of -91.59% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
Hyperion DeFi	N/A	-91.59%	-73.08%

Bullfrog AI has higher earnings, but lower revenue than Hyperion DeFi. Bullfrog AI is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116.67K	102.57	-$6.50M	-$0.54	N/A
Hyperion DeFi	$810K	51.28	-$45.31M	-$9.95	N/A

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by insiders. Comparatively, 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bullfrog AI has a beta of -2.8, suggesting that its share price is 380% less volatile than the broader market. Comparatively, Hyperion DeFi has a beta of 2.49, suggesting that its share price is 149% more volatile than the broader market.

Hyperion DeFi has a consensus target price of $6.95, suggesting a potential upside of 153.65%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, analysts clearly believe Hyperion DeFi is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Hyperion DeFi had 4 more articles in the media than Bullfrog AI. MarketBeat recorded 4 mentions for Hyperion DeFi and 0 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 1.43 beat Hyperion DeFi's score of 1.17 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Overall Sentiment
Bullfrog AI	Positive
Hyperion DeFi	Positive

Summary

Hyperion DeFi beats Bullfrog AI on 10 of the 15 factors compared between the two stocks.

How does Bullfrog AI compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Alterity Therapeutics' return on equity of 0.00% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Bullfrog AI	N/A	-217.80%	-174.57%

Bullfrog AI has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Bullfrog AI	$116.67K	102.57	-$6.50M	-$0.54	N/A

Alterity Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.8, indicating that its share price is 380% less volatile than the broader market.

Alterity Therapeutics presently has a consensus target price of $13.00, indicating a potential upside of 161.04%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alterity Therapeutics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Bullfrog AI's average media sentiment score of 1.43 beat Alterity Therapeutics' score of 1.25 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Overall Sentiment
Alterity Therapeutics	Positive
Bullfrog AI	Positive

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Alterity Therapeutics beats Bullfrog AI on 8 of the 11 factors compared between the two stocks.

Get Bullfrog AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRG vs. The Competition

Export

Metric	Bullfrog AI	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.72M	$1.82B	$6.89B	$12.44B
Dividend Yield	N/A	N/A	2.67%	8.84%
P/E Ratio	-1.20	76.31	27.14	23.91
Price / Sales	102.57	7.57	524.01	90.57
Price / Cash	N/A	27.48	51.46	60.07
Price / Book	3.40	5.44	10.69	6.18
Net Income	-$6.50M	-$54.76M	$3.59B	$331.95M
7 Day Performance	-6.46%	-2.18%	-2.18%	-2.05%
1 Month Performance	-10.68%	1.89%	1.63%	-2.14%
1 Year Performance	-57.26%	-1.83%	25.58%	17.28%

Bullfrog AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRG Bullfrog AI	1.4846 of 5 stars	$0.65 +2.1%	N/A	-57.0%	$11.72M	$116.67K	N/A	4	Positive News Short Interest Decrease
MGX Metagenomi	2.9296 of 5 stars	$1.32 -0.4%	$7.00 +432.3%	-41.8%	$49.51M	$25.21M	N/A	236
SCYX SCYNEXIS	2.5407 of 5 stars	$4.88 -1.1%	$24.00 +392.3%	-27.9%	$48.41M	$20.60M	N/A	60	Positive News
DWTX Dogwood Therapeutics	2.3696 of 5 stars	$1.40 -2.4%	$12.00 +760.2%	-71.0%	$46.91M	N/A	N/A	5
HYPD Hyperion DeFi	3.8965 of 5 stars	$3.01 +1.7%	$6.95 +130.9%	-82.7%	$45.63M	$810K	N/A	40	News Coverage Positive News Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRG) was last updated on 7/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bullfrog AI (BFRG) Competitors

BFRG vs. MGX, SCYX, DWTX, HYPD, and ATHE

How does Bullfrog AI compare to Metagenomi?

Summary

How does Bullfrog AI compare to SCYNEXIS?

Summary

How does Bullfrog AI compare to Dogwood Therapeutics?

Summary

How does Bullfrog AI compare to Hyperion DeFi?

Summary

How does Bullfrog AI compare to Alterity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG vs. The Competition

Bullfrog AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bullfrog AI (BFRG) Competitors

BFRG vs. MGX, SCYX, DWTX, HYPD, and ATHE

How does Bullfrog AI compare to Metagenomi?

Do insiders & institutionals hold more shares of MGX or BFRG?

Which has more volatility & risk, MGX or BFRG?

Does the media prefer MGX or BFRG?

Is MGX or BFRG more profitable?

Do analysts rate MGX or BFRG?

Which has stronger earnings & valuation, MGX or BFRG?

Summary

How does Bullfrog AI compare to SCYNEXIS?

Which has more risk and volatility, SCYX or BFRG?

Is SCYX or BFRG more profitable?

Do institutionals and insiders believe in SCYX or BFRG?

Which has better earnings and valuation, SCYX or BFRG?

Does the media favor SCYX or BFRG?

Do analysts rate SCYX or BFRG?

Summary

How does Bullfrog AI compare to Dogwood Therapeutics?

Does the media refer more to BFRG or DWTX?

Which has more risk and volatility, BFRG or DWTX?

Is BFRG or DWTX more profitable?

Do analysts prefer BFRG or DWTX?

Do institutionals & insiders hold more shares of BFRG or DWTX?

Which has preferable earnings & valuation, BFRG or DWTX?

Summary

How does Bullfrog AI compare to Hyperion DeFi?

Is BFRG or HYPD more profitable?

Which has stronger valuation and earnings, BFRG or HYPD?

Do insiders & institutionals have more ownership in BFRG or HYPD?

Which has more risk and volatility, BFRG or HYPD?

Do analysts prefer BFRG or HYPD?

Does the media refer more to BFRG or HYPD?

Summary

How does Bullfrog AI compare to Alterity Therapeutics?

Is ATHE or BFRG more profitable?

Which has higher valuation & earnings, ATHE or BFRG?

Which has more risk and volatility, ATHE or BFRG?

Do analysts recommend ATHE or BFRG?

Does the media prefer ATHE or BFRG?

Do insiders and institutionals believe in ATHE or BFRG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG vs. The Competition

Bullfrog AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools